Screener
Adaptive Biotechnologies ADPT Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206546
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accounts receivable, net | 48,315 | 50,365 |
| Inventory | 11,206 | 9,820 |
| Prepaid expenses and other current assets | 13,952 | 13,020 |
| Total current assets | 291,807 | 300,185 |
| Long-term assets | ||
| Property and equipment, net | 30,774 | 34,107 |
| Operating lease right-of-use assets | 40,248 | 40,616 |
| Long-term marketable securities (amortized cost of $18,908 and $13,220, respectively) | 18,889 | 13,234 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Adaptive Biotechnologies's total current assets?
- Adaptive Biotechnologies (ADPT) reported total current assets of $291.81M in Q1 2026.
- How has Adaptive Biotechnologies's total current assets changed year-over-year?
- Adaptive Biotechnologies's total current assets increased by 13.8% year-over-year, from $256.49M to $291.81M.
- What is the long-term trend for Adaptive Biotechnologies's total current assets?
- Over 5 years (2020 to 2025), Adaptive Biotechnologies's total current assets has grown at a -16.2% compound annual growth rate (CAGR), from $726.91M to $300.19M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Adaptive Biotechnologies's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude